Pharsight

Abbvie Inc patents expiration

1. Combigan patents expiration

COMBIGAN's oppositions filed in EPO
COMBIGAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7642258 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9770453 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US8133890 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US7030149 ABBVIE INC Combination of brimonidine timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US9474751 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US9907802 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US8748425 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US8354409 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US7320976 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US9907801 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Apr, 2022

(1 year, 10 months ago)

US7323463 ABBVIE INC Combination of brimonidine and timolol for topical ophthalmic use
Jan, 2023

(1 year, 1 month ago)

Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient

Market Authorisation Date: 30 October, 2007

Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension, with comparable efficacy, and a reduction in specified adverse events, compared to brimonidine 0.2% t...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of COMBIGAN before it's drug patent expiration?
More Information on Dosage

COMBIGAN family patents

Family Patents

2. Lumigan patents expiration

LUMIGAN's oppositions filed in EPO
LUMIGAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7851504 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Jun, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241918 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8933120 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8278353 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8299118 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8772338 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8338479 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US9155716 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8586630 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8309605 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8524777 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

US8933127 ABBVIE INC Enhanced bimatoprost ophthalmic solution
Mar, 2025

(1 year, 20 days from now)

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 31 August, 2010

Treatment: Method of treating glaucoma or elevated intraocular pressure; A method of treating a patient with glaucoma or ocular hypertension; A method of lowering intraocular pressure; A method of reducing intra...

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIGAN before it's drug patent expiration?
More Information on Dosage

LUMIGAN family patents

Family Patents

3. Mavyret patents expiration

MAVYRET's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(7 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(8 years from now)

USRE48923 ABBVIE INC Crystal forms
May, 2035

(11 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039754 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US10028937 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US9586978 ABBVIE INC Anti-viral compounds
Nov, 2030

(6 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(6 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(6 years from now)

US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds
May, 2031

(7 years from now)

US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(8 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds
Nov, 2032

(8 years from now)

US10286029 ABBVIE INC Method for treating HCV
Mar, 2034

(10 years from now)

US11484534 ABBVIE INC Methods for treating HCV
Mar, 2034

(10 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV
Sep, 2034

(10 years from now)

US11484534

(Pediatric)

ABBVIE INC Methods for treating HCV
Sep, 2034

(10 years from now)

USRE48923

(Pediatric)

ABBVIE INC Crystal forms
Nov, 2035

(11 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms
Dec, 2035

(11 years from now)

US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV
Jun, 2036

(12 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
Pediatric Exclusivity (PED) Dec 10, 2028

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older ...

Dosage: PELLETS;ORAL

More Information on Dosage

MAVYRET family patents

Family Patents

4. Oriahnn (copackaged) patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(6 months from now)

US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11459305 ABBVIE INC Processes for the preparation of uracil derivatives
Nov, 2028

(4 years from now)

US11045470 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(10 years from now)

US10881659 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023
New Product (NP) May 29, 2023

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 29 May, 2020

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage

ORIAHNN (COPACKAGED) family patents

Family Patents

5. Orilissa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7056927 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Sep, 2024

(6 months from now)

US7419983 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods related thereto
Jul, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176211 ABBVIE INC Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Jul, 2024

(4 months from now)

US11344551 ABBVIE INC Methods of treating heavy menstrual bleeding
Mar, 2034

(10 years from now)

US10537572 ABBVIE INC Methods of administering elagolix
Sep, 2036

(12 years from now)

US10682351 ABBVIE INC Methods of administering elagolix
Sep, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 23, 2023

Drugs and Companies using ELAGOLIX SODIUM ingredient

NCE-1 date: 2022-07-23

Market Authorisation Date: 23 July, 2018

Treatment: Management of moderate to severe pain associated with endometriosis; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with endometriosis in premenopausal women to r...

Dosage: TABLET;ORAL

How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage

ORILISSA family patents

Family Patents

6. Qulipta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(8 years from now)

US9850246 ABBVIE INC Process for making CGRP receptor antagonists
Mar, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Apr 17, 2026
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: 2025-09-28

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

More Information on Dosage

QULIPTA family patents

Family Patents

7. Rinvoq patents expiration

RINVOQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47221 ABBVIE INC Tricyclic compounds
Dec, 2030

(6 years from now)

US8962629 ABBVIE INC Tricyclic compounds
Jan, 2031

(6 years from now)

US11186584 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US9951080 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10981923 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11365198 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US9963459 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof
Oct, 2036

(12 years from now)

US10730883 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10344036 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10981924 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11512092 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10519164 ABBVIE INC Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US11198697 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10202393 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10597400 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10995095 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof
Oct, 2036

(12 years from now)

US10550126 ABBVIE INC Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Oct, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 16, 2024
New Indication (I) Jan 14, 2025

Drugs and Companies using UPADACITINIB ingredient

NCE-1 date: 2023-08-17

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active non-radiographic axial spondyloarthr...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

RINVOQ family patents

Family Patents

8. Technivie patents expiration

TECHNIVIE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(7 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US8399015

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(1 year, 1 day from now)

US8268349

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form
Feb, 2025

(1 year, 1 day from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(7 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(7 years from now)

US8420596

(Pediatric)

ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Oct, 2031

(7 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

More Information on Dosage

TECHNIVIE family patents

Family Patents

9. Ubrelvy patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9499545 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(8 years from now)

US8912210 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Dec, 2033

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833448 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Nov, 2031

(7 years from now)

US10117836 ABBVIE INC Tablet formulation for CGRP active compounds
Jan, 2035

(10 years from now)

US11717515 ABBVIE INC Treatment of migraine
Dec, 2041

(17 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: 2023-12-24

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with or without aura in adults; Acute treatment of migraine with or without aura in a patient with severe hepatic impairment; Acute treatment of migraine with headache, wit...

Dosage: TABLET;ORAL

More Information on Dosage

UBRELVY family patents

Family Patents

10. Venclexta patents expiration

VENCLEXTA's oppositions filed in EPO
VENCLEXTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8546399 ABBVIE INC Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
Jun, 2031

(7 years from now)

US10730873 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Nov, 2031

(7 years from now)

US8722657 ABBVIE INC Salts and crystalline forms of an apoptosis-inducing agent
Jan, 2032

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9174982 ABBVIE INC Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
May, 2030

(6 years from now)

US11369599 ABBVIE INC Melt-extruded solid dispersions containing an apoptosis-inducing agent
May, 2032

(8 years from now)

US9539251 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

US11413282 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

US11110087 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor
Sep, 2033

(9 years from now)

US10993942 ABBVIE INC Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) May 15, 2026

Drugs and Companies using VENETOCLAX ingredient

Market Authorisation Date: 11 April, 2016

Treatment: Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment in combination with azacitidine or decitabine or low-dose cytarabine of newly-diagnos...

Dosage: TABLET;ORAL

How can I launch a generic of VENCLEXTA before it's drug patent expiration?
More Information on Dosage

VENCLEXTA family patents

Family Patents

11. Viekira Pak (copackaged) patents expiration

VIEKIRA PAK (COPACKAGED)'s oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Dec, 2028

(4 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(5 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(7 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof
Nov, 2028

(4 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(7 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(7 years from now)

US8685984 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8492386 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8466159 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8680106 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US10201542 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(9 years from now)

US9629841 ABBVIE INC Formulations of pyrimidinedione derivative compounds
Oct, 2033

(9 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using paritaprevir, ombitasvir, riton...

Dosage: TABLET;ORAL

More Information on Dosage

VIEKIRA PAK (COPACKAGED) family patents

Family Patents

12. Viekira Xr patents expiration

VIEKIRA XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8501238 ABBVIE INC Anti-infective agents and uses thereof
Sep, 2028

(4 years from now)

US8188104 ABBVIE INC Anti-infective agents and uses thereof
May, 2029

(5 years from now)

US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(5 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(7 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8268349 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US8399015 ABBVIE INC Solid pharmaceutical dosage form
Aug, 2024

(5 months from now)

US9139536 ABBVIE INC Anti-infective agents and uses thereof
Nov, 2028

(4 years from now)

US9006387 ABBVIE INC Anti-viral compounds
Jun, 2030

(6 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV
Apr, 2031

(7 years from now)

US8686026 ABBVIE INC Solid compositions
Jun, 2031

(7 years from now)

US10201584 ABBVIE INC Compositions and methods for treating HCV
May, 2032

(8 years from now)

US10201541 ABBVIE INC Compositions and methods for treating HCV
May, 2032

(8 years from now)

US8492386 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8685984 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8466159 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US8680106 ABBVIE INC Methods for treating HCV
Sep, 2032

(8 years from now)

US9333204 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(10 years from now)

US9744170 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(10 years from now)

US10105365 ABBVIE INC Solid antiviral dosage forms
Jan, 2035

(10 years from now)

Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 22 July, 2016

Treatment: Treatment of hcv infection using dasabuvir; Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir; Treatment of hcv infection using dasabuvir/ombitasvir/paritaprev...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VIEKIRA XR family patents

Family Patents

13. Vuity patents expiration

VUITY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11285134 ABBVIE INC Presbyopia treatments
Apr, 2039

(15 years from now)

US10610518 ABBVIE INC Presbyopia treatments
Apr, 2039

(15 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule (D) Mar 28, 2026
New Product (NP) Oct 28, 2024

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2021

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION;OPHTHALMIC

How can I launch a generic of VUITY before it's drug patent expiration?
More Information on Dosage

VUITY family patents

Family Patents